Lilly launches Foundayo oral GLP-1 weight loss pill in US market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026 6:45 AM EDTFoundayo is now available via LillyDirect® and telehealth providers and is shipping to retail pharmacies nationwide
Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, starts at $25 per month with commercial coverage and $149 per month with self-pay
INDIANAPOLIS, April 9, 2026 /PRNewswire/ --... More
